Previous 10 | Next 10 |
Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum Natera to Present at the Canaccord Genuity Virtual MedTech & Diagnostics Forum PR Newswire SAN CARLOS, Calif., Nov. 12, 2020 SAN CARLOS, Calif. , Nov. 12, 2020 /PRNewsw...
Natera Presents New Data at the 2020 SITC Annual Meeting Highlighting Applications of Personalized ctDNA Testing in Immunotherapy Treatment Monitoring Clinical case studies demonstrate the performance of the Signatera™ test in cancer patients receiving immunotherapy P...
Natera, Inc. (NTRA) Q3 2020 Earnings Conference Call November 5, 2020 16:30 ET Company Participants Steve Chapman - Chief Executive Officer Michael Brophy - Chief Financial Officer Solomon Moshkevich - General Manager, Oncology Paul Billings - Chief Medical Officer Conference Call Participant...
The following slide deck was published by Natera, Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Natera, Inc. 2020 Q3 - Results - Earnings Call Presentation
Natera (NTRA): Q3 GAAP EPS of -$0.72 misses by $0.04.Revenue of $98.1M (+25.9% Y/Y) beats by $10.86M.FY2020 guidance: Total revenue of $380M-$390M vs consensus of $359.6M; 2020 cost of revenues of ~51%-54% of revenues; selling, general and administrative costs of ~$270M-$280M; research and de...
Natera Reports Third Quarter 2020 Financial Results PR Newswire SAN CARLOS, Calif., Nov. 5, 2020 SAN CARLOS, Calif. , Nov. 5, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today reported financia...
Natera (NASDAQ:NTRA) is scheduled to announce Q3 earnings results on Thursday, November 5th, after market close.The consensus EPS Estimate is -$0.70 (-112.1% Y/Y) and the consensus Revenue Estimate is $87.24M (+12.0% Y/Y).Over the last 1 year, NTRA has beaten EPS estimates 50% of the time and...
International Society for Prenatal Diagnosis Recommends cfDNA Screening in Twin Pregnancies Recommends incorporating zygosity, a capability unique to the Panorama® test, into clinical practice PR Newswire SAN CARLOS, Calif., Oct. 30, 2020 SAN CARLOS, Calif...
Natera Announces Third Quarter 2020 Earnings Conference Call PR Newswire SAN CARLOS, Calif., Oct. 28, 2020 SAN CARLOS, Calif. , Oct. 28, 2020 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today anno...
NIPT for Average Risk Now Covered for 139 Million Commercial Lives Top 5 payor changes medical policy following recent ACOG guideline PR Newswire SAN CARLOS, Calif., Oct. 29, 2020 SAN CARLOS, Calif. , Oct. 29, 2020 /PRNewswire/ -- Natera, Inc. (NA...
News, Short Squeeze, Breakout and More Instantly...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...